3 October 2024

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

CYCLOPHARM SIGNS AGREEMENT WITH US VETERANS ADMINISTRATION AND RECEIVES FIRST TECHNEGAS ORDER FROM THE US DEPARTMENT OF DEFENSE

Cyclopharm Limited (ASX: CYC) is pleased to announce it has entered into an Interim Agreement (IA) to supply the Veterans Health Administration (VA), the largest integrated US Government health care system in the United States (US), for the pharmaceutical and consumable components of Technegas.

The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for these products.

This IA, which Cyclopharm has negotiated directly with the US Department of Veteran Affairs, is the first step to Technegas' inclusion on the broader US Federal Supply Schedule (FSS). The FSS is the simplified procurement service for US federal agencies to obtain products across the entire US Government system, including the Department of Defense (DoD), Veterans Administration (VA), and Public Health Service (PHS) hospitals.

Cyclopharm CEO James McBrayer said, "Securing this Interim Agreement is critical for streamlining the United States Federal Government procurement process. This agreement bypasses the need for Cyclopharm to negotiate separate contracts with each of the 20 Regional Procurement Offices within the VA or potentially follow a reseller pathway that would delay the deployment of Technegas, distance us from our customers and impact margins beyond the legislated discounts required for federal contracts."

"Throughout this process, we have leveraged our commercial experience and success in the 65 other countries where Technegas is the preferred agent of choice. In these markets, complementary and evolving technologies are continually expanding Technegas' indications for use in respiratory medicine. This direct VA agreement is evidence of the traction we continue to gain in the US, which is largest nuclear medicine market globally."

In parallel with the IA covering the pharmaceutical component agreement, Cyclopharm is also progressing with the necessary registrations to include the Technegas System, the medical device component of Technegas, in the same streamlined process.

In relation to the patients linked to this agreement, Technegas' ability to provide highly accurate functional ventilation images is a key diagnostic aid for conditions such as chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, a condition affecting veterans impacted by toxic exposures during active service. By improving diagnostic accuracy, Technegas

will aid in the VA's effective treatment and management of lung disease in affected veterans, enhancing care under the PACT Act[1].

Cyclopharm also announces today the receipt of its first purchase order for Technegas from a Department of Defense (DoD) hospital. While DoD facilities will be covered under the upcoming FSS agreement, the company has in parallel been progressing Technegas implementation at individual sites across the VA, DoD and PHS networks.

As a result of this agreement with the VA and receipt of its first purchase order from the DoD, initial installations at VA, DoD and PHS sites are anticipated to commence in the first half of 2025, representing another key revenue deliverable in Cyclopharm's US strategy.

ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:
TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.

[1] PACT Act – 1.Expands and extends eligibility for VA health care for Veterans with toxic exposures and Veterans of the Vietnam era, Gulf War era, and Post-9/11 era. 2. Expands eligibility for benefits for Veterans exposed to toxic substances (https://www.va.gov/files/2023-08/PACT%20Act%20Overview%20101_v11.7.22%20%281%29.pdf)